MiniMed Group posts Q4 loss of $0.68 per share as revenue rises to $837 million, missing EPS but beating sales estimates
- FY26 results described as strong, with net sales above $3B.
- Company extended its diabetes partnership with Abbott, building on existing collaboration.
- MiniMed issued 2027 growth and margin guidance alongside its Q4 and FY26 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.